HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Patel, S. Articles by Thomas, A. P. Search for Related Content PubMed PubMed Citation Articles by Patel, S. Articles by Thomas, A. P.

J Biol Chem, Vol. 273, Issue 6, 3121-3124, February 6, 1998

COMMUNICATION
Decorin Activates the Epidermal Growth Factor Receptor and Elevates Cytosolic Ca²⁺ in A431 Carcinoma Cells^*

Sandip Patel^§, Manoranjan Santra, David J. McQuillan^¶, Renato V. Iozzo^**, and Andrew P. Thomas^**

From the  Department of Pathology, Anatomy and Cell Biology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, the ^¶ Center for Extracellular Matrix Biology, Institute of Biosciences and Technology, Texas A & M University, Houston, Texas 77030, and the  Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107

	ABSTRACT

Top Abstract Introduction Procedures Results & Discussion References

Several independent lines of evidence have implicated decorin, a small leucine-rich proteoglycan, in the inhibition of cell proliferation. However, the mechanism by which decorin mediates its effect on cell proliferation is unclear. Here we report, for the first time, decorin-mediated increases in intracellular Ca²⁺ levels of single A431 cells. The effects of decorin persisted in the absence of extracellular Ca²⁺ but were blocked by AG1478, an epidermal growth factor (EGF)-specific tyrosine kinase inhibitor, and by down-regulation of the EGF receptor. The effects of decorin were not mimicked by the structurally homologous protein, biglycan. Our results indicate a novel action of decorin on the EGF receptor, which results in mobilization of intracellular Ca²⁺ providing a possible mechanism by which decorin causes growth suppression.

	INTRODUCTION

Top Abstract Introduction Procedures Results & Discussion References

Stimulation of phospholipase C (PLC)¹ by cell surface receptors results in the generation of the second messenger inositol 1,4,5-trisphosphate and consequent activation of Ca²⁺ channels located within the membrane of intracellular Ca²⁺ stores (1). Growth factors, such as epidermal growth factor (EGF) activate receptor tyrosine kinases, which dimerize, autophosphorylate, and generate inositol 1,4,5-trisphosphate via phosphorylation and consequent stimulation of the PLC- isoform (2). The ensuing increases in the cytosolic Ca²⁺ concentration ([Ca²⁺]_i), which are often both temporally and spatially complex (3), are implicated in a wide range of cellular processes.

Decorin is a key regulator of extracellular matrix assembly and is a member of an expanding family of proteoglycans characterized by a central domain with tandem leucine-rich repeats (4). Molecular modeling has revealed an arch-shaped molecule with a concave surface capable of interacting with various other proteins (5). Targeted disruption of the decorin gene leads to mice with a skin fragility phenotype and altered collagen fibril morphology (6), thereby providing genetic evidence that decorin is a "modifier" of collagen fibrillogenesis during development.

Increasing evidence suggests an inhibitory role for this secreted proteoglycan in cell proliferation (7). In a variety of cell types, overexpression of decorin inhibits cell growth (8, 9). Furthermore, levels of decorin are markedly increased in quiescent cells and reduced in transformed cells (10, 11). Decorin may also play an important role in tumorigenesis, because not only is decorin expression decreased in various tumor cell types, but secretion of decorin by stromal cells surrounding tumors is increased (12). This may represent a response by the host to reduce the rate of carcinoma spread.

Although decorin overexpression is associated with an up-regulation of p21 (13), an inhibitor of cyclin-dependent kinases required for progression through the cell cycle (14), upstream targets for decorin, and the exact mechanism by which decorin inhibits cellular growth are unknown. Recently, we have shown that decorin stimulates phosphorylation of the EGF receptor and activation of the mitogen-activated protein (MAP) kinase pathway (15). Because EGF receptors can couple to PLC, decorin may also elevate [Ca²⁺]_i, implicating a role for Ca²⁺ in the inhibitory effects of decorin on cell proliferation. Here, we report for the first time that activation of the EGF receptor by decorin results in elevation of [Ca²⁺]_i in single A431 squamous carcinoma cells. Therefore, Ca²⁺ signals may be important in mediating decorin-induced growth inhibition, which ultimately may retard tumor progression in vivo.

	EXPERIMENTAL PROCEDURES

Top Abstract Introduction Procedures Results & Discussion References

Materials-- Human squamous carcinoma A431 cells were obtained from ATCC (Rockville, MD). Highly purified human recombinant decorin and biglycan synthesized by human fibrosarcoma HT1080 cells using the vaccinia virus/T7 phage expression system were purified as described previously (16, 17). Fura-2 and Pluronic F-127 acid were from Teflabs, ionomycin was from Calbiochem, and human recombinant EGF was from Life Technologies, Inc. All other reagents were from Sigma or Fisher.

Cell Culture-- A431 cells were cultured on glass coverslips coated with poly-D-lysine (5 µg/cm³) and maintained at 37 °C in Dulbecco's modified Eagle's medium containing 5% fetal calf serum, 2 mM glutamine, 100 units/ml penicillin, and 50 µg/ml streptomycin in an atmosphere of CO₂/air (5%:95%). At 70% confluence, the cells were cultured for a further 48 h in serum-free medium prior to imaging experiments.

Single Cell Ca²⁺ Imaging-- Imaging experiments were performed at room temperature in a medium composed of 121 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO₄, 1.2 mM KH₂PO₄, 10 mM glucose, 2 mM CaCl₂, 0.25% (w/v) bovine serum albumin, and 20 mM HEPES (pH 7.4 at room temperature). [Ca²⁺]_i was determined by loading the cells with fura-2 by incubation with fura-2/acetoxymethyl ester (5 µM) in the presence of Pluronic F-127 acid (0.02% w/v) for 20 min. Coverslips were then mounted on an inverted epifluorescence microscope, and fura-2 was excited at 340 and 380 nm and emission (420-600 nm) collected using a charged coupled device camera. Autofluorescence was determined following quench of fura-2 by Mn²⁺ in Ca²⁺-free medium supplemented with 1 mM MnCl₂ and 2 µM ionomycin. The ratio of the fluorescence at 340 and 380 nm was converted to [Ca²⁺] according to Grynkiewicz et al. (18).

	RESULTS AND DISCUSSION

Top Abstract Introduction Procedures Results & Discussion References

Decorin Increases [Ca²⁺]_i in Single A431 Cells-- We have previously shown that decorin-mediated growth inhibition in A431 cells is associated with phosphorylation of the EGF receptor (15). Generally, EGF stimulates cell growth and proliferation, but the proliferation of certain cells is paradoxically inhibited by this growth factor (19). The prototype of such cells is the A431 human squamous carcinoma cell, which expresses a high number of EGF receptors (~2 × 10⁶/cell) (20). Because activation of EGF receptors results in autophosphorylation and can potentially stimulate PLC-, we examined the effects of decorin on [Ca²⁺]_i in individual fura-2-loaded A431 cells. Fig. 1 demonstrates typical [Ca²⁺]_i increases in response to stimulation of A431 cells with decorin. From five separate cell passages, decorin increased [Ca²⁺]_i in 49 ± 12% of cells. In the 498 responding cells, [Ca²⁺]_i increased from a resting level of 30 ± 1 nM to a peak of 123 ± 3 nM. Similar responses were observed after removal of Ca²⁺ from the extracellular medium (Fig. 1C). These results indicate that decorin mobilizes Ca²⁺ primarily from intracellular stores as opposed to directly stimulating Ca²⁺ entry across the plasma membrane.

View larger version (55K): [in this window] [in a new window]   Fig. 1.   Decorin induces [Ca2+]i increases in single A431 cells. A, the far left panel shows the fluorescence (380 nm) of fura-2-loaded A431 cells depicted on linear gray scale. The other panels show the ratio of fluorescence at 340 and 380 nm, displayed on a pseudo-color scale, before (second panel) and at the times indicated after (third and fourth panels) the addition of decorin (100 µg/ml). The 340/380 nm ratio is directly proportional to [Ca2+]i, where blue indicates low values, and red indicates higher values. Typical increases in [Ca2+]i from individual cells in response to decorin are shown in the presence (B) and the absence (C) of extracellular Ca2+ (2 mM).

Biglycan is another member of the family of small leucine-rich proteoglycans sharing 57% amino acid homology with decorin (4). In contrast to decorin, biglycan did not cause growth inhibition (9) and did not affect [Ca²⁺]_i (Fig. 2). Taken together, these data support a specific effect of decorin on A431 cells.

View larger version (15K): [in this window] [in a new window]   Fig. 2.   Biglycan, a related proteoglycan does not increase [Ca2+]i in single A431 cells. Representative mean [Ca2+]i responses from a field of cells stimulated with 100 µg/ml of either decorin (239 cells) or biglycan (252 cells) as indicated. Both responding and nonresponding cells were included in calculation of the mean [Ca2+]i.

Decorin-induced Responses are Prevented by AG1478, a Specific Inhibitor of EGF Receptor Tyrosine Kinase-- To establish whether decorin-mediated increases in [Ca²⁺]_i were via activation of the EGF receptor, we examined the effects of the tyrphostin AG1478, an EGF-selective tyrosine kinase inhibitor on responses to EGF (21) and decorin (15). From nine separate cell passages, EGF elevated [Ca²⁺]_i in 90 ± 4% of cells from a resting level of 28 ± 1 nM to a peak level of 191 ± 3 nM (1369 responding cells out of 1492 cells, Fig. 3A). Pretreatment of the cells with AG1478 (2 µM) reduced the number of cells responding to EGF (Fig. 3B) by 97 ± 2% (27 responding cells out of 533 cells from five separate cell passages). AG1478 completely abolished the [Ca²⁺]_i responses to decorin (0 responding cells out of 499 cells from two separate cell passages; Fig. 3C). Notably, we used a concentration of AG1478 that is about of that required to inhibit c-src kinase activity (21) but that effectively blocks activation of the EGF receptor kinase and MAP kinase caused by either EGF or exogenous decorin (9). Moreover, we found that MAP kinase activation by platelet-derived growth factor was unaffected by the same concentrations of AG1478 (9). In addition, AG1478 did not affect [Ca²⁺]_i responses to ATP. In five separate cell passages, ATP (200 µM) elevated [Ca²⁺]_i by 776 ± 44 nM (907 cells) and 870 ± 14 nM (670 cells) in the absence and the presence of AG1478, respectively. The inhibitory effects of AG1478 on EGF responses were reversed if AG1478 was washed out 45 min prior to stimulation (not shown).

View larger version (16K): [in this window] [in a new window]   Fig. 3.   Decorin-induced [Ca2+]i increases are abolished by AG1478. A, typical [Ca2+]i increase in response to EGF (100 ng/ml). B and C, pretreatment of cells with the EGF receptor-specific tyrosine kinase inhibitor AG1478 (2 µM) abolishes responses to EGF (100 ng/ml, B) and decorin (100 µg/ml, C) but not to ATP (200 µM).

Decorin Responses Are Inhibited by EGF Receptor Down-regulation-- We next examined the effects of EGF and decorin on [Ca²⁺]_i in A431 cells in which EGF receptors had been down-regulated. Prolonged exposure of cells to EGF has been shown to reduce the number of EGF receptors at the cell surface (22). Under these conditions, the number of cells responding to EGF (Fig. 4A) and decorin (Fig. 4B) was reduced by 96 ± 3% (4 responding cells out of 255 cells from three separate cell passages) and 99% (3 responding cells out of 424 cells from two separate cell passages), respectively. Down-regulation of EGF receptors reduced [Ca²⁺]_i increases in response to ATP by 58 ± 9%.

View larger version (18K): [in this window] [in a new window]   Fig. 4.   EGF receptor down-regulation prevents decorin-induced [Ca2+]i increases. Cells were treated with EGF (100 ng/ml) for 18 h, and then EGF was removed 40 min prior to restimulation. Down-regulation of EGF receptors abolished responses to EGF (100 ng/ml, A) and decorin (100 µg/ml, B) but not to ATP (200 µM).

Our results show that decorin mediates [Ca²⁺]_i increases in A431 cells. These responses may occur in vivo, because the concentration of decorin used in the present study (~1 µM) is much lower than that estimated to be bound to dermal collagen, the site of interaction between keratinocytes and the mesenchyme. The effects of decorin on [Ca²⁺]_i are unlikely to be mediated by activation of integrins, which has been reported previously for other extracellular matrix constituents, because decorin does not contain the tripeptide RGD consensus sequence characteristic of integrin-binding proteins (23). Recent studies have demonstrated that syndecan-4, a transmembrane proteoglycan, can activate protein kinase C (24, 25). Our results, however, are consistent with decorin activating PLC- via the EGF receptor, because decorin mediates [Ca²⁺]_i increases that are abolished by either inhibition of EGF receptors with AG1478 or down-regulation of EGF receptors. Because EGF also inhibits proliferation in this cell type, our results provide a possible mechanism by which decorin mediates its negative effects involving direct activation of the EGF receptor and increases in cytosolic Ca²⁺.

	ACKNOWLEDGEMENTS

We thank D. Moscatello, A. Morgan, and L. D. Robb-Gaspers for helpful discussions.

	FOOTNOTES

^* This work was supported by National Institutes of Health Grants RO1 DK38422 (to A. P. T.), RO1 CA39481 (to R. V. I.), and RO1 CA47282 (to R. V. I.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^§ Recipient of a Wellcome Prize Traveling Research Fellowship (UK).

^** To whom correspondence should be addressed: Dept. of Pathology, Anatomy and Cell Biology, Jefferson Alumni Hall, Thomas Jefferson University, 1020 Locust St., Philadelphia, PA 19107. Fax: 215-923-2218; E-mail: Iozzo{at}lac.jci.tju.edu or Thomasap{at}umdnj.edu.

¹ The abbreviations used are: PLC, phospholipase C; EGF, epidermal growth factor; MAP, mitogen-activated protein.

	REFERENCES

Top Abstract Introduction Procedures Results & Discussion References

1. Berridge, M. J. (1993) Nature 361, 315-325[CrossRef][Medline] [Order article via Infotrieve]
2. Schlesinger, J., and Ullrich, A. (1992) Neuron 9, 383-391[CrossRef][Medline] [Order article via Infotrieve]
3. Thomas, A. P., Bird, G., St, J., Hajnóczky, G., Robb-Gaspers, L. D., Putney, J. W. (1996) FASEB J. 10, 1505-1517[Abstract]
4. Iozzo, R. V. (1997) Crit. Rev. Biochem. Mol. Biol. 32, 141-174[Medline] [Order article via Infotrieve]
5. Weber, I. T., Harrison, R. W., and Iozzo, R. V. (1996) J. Biol. Chem. 271, 31767-31770[Abstract/Free Full Text]
6. Danielson, K. G., Baribault, H., Holmes, D. F., Graham, H., Kadler, K. E., Iozzo, R. V. (1997) J. Cell Biol. 136, 729-743[Abstract/Free Full Text]
7. Iozzo, R. V., and Murdoch, A. D. (1996) FASEB J. 10, 598-614[Abstract]
8. Santra, M., Skorski, T., Calabretta, B., Lattime, E. C., Iozzo, R. V. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 7016-7020[Abstract/Free Full Text]
9. Santra, M., Mann, D. M., Mercer, E. W., Skorski, T., Calabretta, B., Iozzo, R. V. (1997) J. Clin. Invest. 100, 149-157[Medline] [Order article via Infotrieve]
10. Mauviel, A., Santra, M., Chen, Y. Q., Uitto, J., Iozzo, R. V. (1995) J. Biol. Chem. 270, 11692-11700[Abstract/Free Full Text]
11. Coppock, D. L., Kopman, C., Scandalis, S., and Gilleran, S. (1993) Cell Growth Differ. 4, 483-493[Abstract]
12. Adany, R., Heimer, R., Caterson, B., Sorrell, J. M., Iozzo, R. V. (1990) J. Biol. Chem. 265, 11389-11396[Abstract/Free Full Text]
13. De Luca, A., Santra, M., Baldi, A., Giordano, A., and Iozzo, R. V. (1996) J. Biol. Chem. 271, 18961-18965[Abstract/Free Full Text]
14. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., Vogelstein, B. (1993) Cell 75, 817-825[CrossRef][Medline] [Order article via Infotrieve]
15. Moscatello, D. K., Santra, M., Mann, D. M., McQuillan, D. J., Wong, A. J., and Iozzo, R. V. (1997) J. Clin. Invest., in press
16. Hocking, A. M., Strugnell, R. A., Ramamurthy, P., and McQuillan, D. J. (1996) J. Biol. Chem. 271, 19571-19577[Abstract/Free Full Text]
17. Ramamurthy, P., Hocking, A. M., and McQuillan, D. J. (1996) J. Biol. Chem. 271, 19578-19584[Abstract/Free Full Text]
18. Grynkiewicz, G., Poenie, M., and Tsien, R. Y. (1985) J. Biol. Chem. 260, 3440-3450[Abstract/Free Full Text]
19. Barnes, D. W. (1982) J. Cell Biol. 93, 1-4[Abstract/Free Full Text]
20. Fan, Z., Lu, Y., Wu, X., DeBlasio, A., Koff, A., and Mendelsohn, J. (1995) J. Cell Biol. 131, 235-242[Abstract/Free Full Text]
21. Levitzki, A., and Gazit, A. (1995) Science 267, 1782-1788[Abstract/Free Full Text]
22. Carpenter, G. (1987) Annu. Rev. Biochem. 56, 881-914[CrossRef][Medline] [Order article via Infotrieve]
23. Sjaastad, M. D., and Nelson, W. J. (1997) BioEssays 19, 47-55[CrossRef][Medline] [Order article via Infotrieve]
24. Oh, E.-S., Woods, A., and Couchman, J. R. (1997) J. Biol. Chem. 272, 8133-8136[Abstract/Free Full Text]
25. Oh, E.-S., Woods, A., and Couchman, J. R. (1997) J. Biol. Chem. 272, 11805-11811[Abstract/Free Full Text]

---

Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

This article has been cited by other articles:

				M. S. Ludwig Proteoglycans and pathophysiology J Appl Physiol, September 1, 2007; 103(3): 735 - 736. [Full Text] [PDF]

				L. Schaefer, W. Tsalastra, A. Babelova, M. Baliova, J. Minnerup, L. Sorokin, H.-J. Grone, D. P. Reinhardt, J. Pfeilschifter, R. V. Iozzo, et al. Decorin-Mediated Regulation of Fibrillin-1 in the Kidney Involves the Insulin-Like Growth Factor-I Receptor and Mammalian Target of Rapamycin Am. J. Pathol., January 1, 2007; 170(1): 301 - 315. [Abstract] [Full Text] [PDF]

				E. Brandan, C. Retamal, C. Cabello-Verrugio, and M.-P. Marzolo The Low Density Lipoprotein Receptor-related Protein Functions as an Endocytic Receptor for Decorin J. Biol. Chem., October 20, 2006; 281(42): 31562 - 31571. [Abstract] [Full Text] [PDF]

				E. C. Carlson, C.-Y. Liu, T.-i. Chikama, Y. Hayashi, C. W.-C. Kao, D. E. Birk, J. L. Funderburgh, J. V. Jester, and W. W.-Y. Kao Keratocan, a Cornea-specific Keratan Sulfate Proteoglycan, Is Regulated by Lumican J. Biol. Chem., July 8, 2005; 280(27): 25541 - 25547. [Abstract] [Full Text] [PDF]

				E. Schonherr, C. Sunderkotter, R. V. Iozzo, and L. Schaefer Decorin, a Novel Player in the Insulin-like Growth Factor System J. Biol. Chem., April 22, 2005; 280(16): 15767 - 15772. [Abstract] [Full Text] [PDF]

				Y. Li, T. Aoki, Y. Mori, M. Ahmad, H. Miyamori, T. Takino, and H. Sato Cleavage of Lumican by Membrane-Type Matrix Metalloproteinase-1 Abrogates This Proteoglycan-Mediated Suppression of Tumor Cell Colony Formation in Soft Agar Cancer Res., October 1, 2004; 64(19): 7058 - 7064. [Abstract] [Full Text] [PDF]

				J. Koninger, N. A. Giese, F. F. di Mola, P. Berberat, T. Giese, I. Esposito, M. G. Bachem, M. W. Buchler, and H. Friess Overexpressed Decorin in Pancreatic Cancer: Potential Tumor Growth Inhibition and Attenuation of Chemotherapeutic Action Clin. Cancer Res., July 15, 2004; 10(14): 4776 - 4783. [Abstract] [Full Text] [PDF]

				D. Alvarado, A. H. Rice, and J. B. Duffy Bipartite Inhibition of Drosophila Epidermal Growth Factor Receptor by the Extracellular and Transmembrane Domains of Kekkon1 Genetics, May 1, 2004; 167(1): 187 - 202. [Abstract] [Full Text] [PDF]

				C. Ghiglione, L. Amundadottir, M. Andresdottir, D. Bilder, J. A. Diamonti, S. Noselli, N. Perrimon, and K. L. Carraway III Mechanism of inhibition of the Drosophila and mammalian EGF receptors by the transmembrane protein Kekkon 1 Development, September 15, 2003; 130(18): 4483 - 4493. [Abstract] [Full Text] [PDF]

				G. J. Jenniskens, M. Ringvall, W. J. H. Koopman, J. Ledin, L. Kjellen, P. H. G. M. Willems, E. Forsberg, J. H. Veerkamp, and T. H. van Kuppevelt Disturbed Ca2+ kinetics in N-deacetylase/N-sulfotransferase-1 defective myotubes J. Cell Sci., June 1, 2003; 116(11): 2187 - 2193. [Abstract] [Full Text] [PDF]

				M. Santra, C. C. Reed, and R. V. Iozzo Decorin Binds to a Narrow Region of the Epidermal Growth Factor (EGF) Receptor, Partially Overlapping but Distinct from the EGF-binding Epitope J. Biol. Chem., September 13, 2002; 277(38): 35671 - 35681. [Abstract] [Full Text] [PDF]

				S. Patel, L. D. Gaspers, S. Boucherie, E. Memin, K. A. Stellato, G. Guillon, L. Combettes, and A. P. Thomas Inducible Nitric-oxide Synthase Attenuates Vasopressin-dependent Ca2+ Signaling in Rat Hepatocytes J. Biol. Chem., September 6, 2002; 277(37): 33776 - 33782. [Abstract] [Full Text] [PDF]

				G. Guidetti, A. Bertoni, M. Viola, E. Tira, C. Balduini, and M. Torti The small proteoglycan decorin supports adhesion and activation of human platelets Blood, August 13, 2002; 100(5): 1707 - 1714. [Abstract] [Full Text] [PDF]

				G. Xu, M.-J. Guimond, C. Chakraborty, and P. K. Lala Control of Proliferation, Migration, and Invasiveness of Human Extravillous Trophoblast by Decorin, a Decidual Product Biol Reprod, August 1, 2002; 67(2): 681 - 689. [Abstract] [Full Text] [PDF]

				M. A. Nash, M. T. Deavers, and R. S. Freedman The Expression of Decorin in Human Ovarian Tumors Clin. Cancer Res., June 1, 2002; 8(6): 1754 - 1760. [Abstract] [Full Text] [PDF]

				G. Carpenter Employment of the Epidermal Growth Factor Receptor in Growth Factor-independent Signaling Pathways J. Cell Biol., January 11, 2002; 146(4): 697 - 702. [Abstract] [Full Text] [PDF]

				N. A. WAHAB, S. PARKER, J.-D. SRAER, and R. M. MASON The Decorin High Glucose Response Element and Mechanism of Its Activation in Human Mesangial Cells J. Am. Soc. Nephrol., September 1, 2000; 11(9): 1607 - 1619. [Abstract] [Full Text]

				J. W. Fischer, M. G. Kinsella, M. M. Clowes, S. Lara, A. W. Clowes, and T. N. Wight Local Expression of Bovine Decorin by Cell-Mediated Gene Transfer Reduces Neointimal Formation After Balloon Injury in Rats Circ. Res., March 31, 2000; 86(6): 676 - 683. [Abstract] [Full Text]

				M. A. Bowe, D. B. Mendis, and J. R. Fallon The Small Leucine-rich Repeat Proteoglycan Biglycan Binds to {alpha}-Dystroglycan and Is Upregulated in Dystrophic Muscle J. Cell Biol., February 21, 2000; 148(4): 801 - 810. [Abstract] [Full Text] [PDF]

				R. V. Iozzo The Biology of the Small Leucine-rich Proteoglycans. FUNCTIONAL NETWORK OF INTERACTIVE PROTEINS J. Biol. Chem., July 2, 1999; 274(27): 18843 - 18846. [Full Text] [PDF]

				P. Krishnan, A. M. Hocking, J. M. Scholtz, C. N. Pace, K. K. Holik, and D. J. McQuillan Distinct Secondary Structures of the Leucine-rich Repeat Proteoglycans Decorin and Biglycan. GLYCOSYLATION-DEPENDENT CONFORMATIONAL STABILITY J. Biol. Chem., April 16, 1999; 274(16): 10945 - 10950. [Abstract] [Full Text] [PDF]

				R. V. Iozzo, F. Chakrani, D. Perrotti, D. J. McQuillan, T. Skorski, B. Calabretta, and I. Eichstetter Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis PNAS, March 16, 1999; 96(6): 3092 - 3097. [Abstract] [Full Text] [PDF]

				C. T. Brown, M. A. Nugent, F. W. Lau, and V. Trinkaus-Randall Characterization of Proteoglycans Synthesized by Cultured Corneal Fibroblasts in Response to Transforming Growth Factor beta  and Fetal Calf Serum J. Biol. Chem., March 12, 1999; 274(11): 7111 - 7119. [Abstract] [Full Text] [PDF]

				R. V. Iozzo, D. K. Moscatello, D. J. McQuillan, and I. Eichstetter Decorin Is a Biological Ligand for the Epidermal Growth Factor Receptor J. Biol. Chem., February 19, 1999; 274(8): 4489 - 4492. [Abstract] [Full Text] [PDF]

				G. Csordas, M. Santra, C. C. Reed, I. Eichstetter, D. J. McQuillan, D. Gross, M. A. Nugent, G. Hajnoczky, and R. V. Iozzo Sustained Down-regulation of the Epidermal Growth Factor Receptor by Decorin. A MECHANISM FOR CONTROLLING TUMOR GROWTH IN VIVO J. Biol. Chem., October 13, 2000; 275(42): 32879 - 32887. [Abstract] [Full Text] [PDF]

				M. Santra, I. Eichstetter, and R. V. Iozzo An Anti-oncogenic Role for Decorin. DOWN-REGULATION OF ErbB2 LEADS TO GROWTH SUPPRESSION AND CYTODIFFERENTIATION OF MAMMARY CARCINOMA CELLS J. Biol. Chem., November 3, 2000; 275(45): 35153 - 35161. [Abstract] [Full Text] [PDF]

				E. Schonherr, B. Levkau, L. Schaefer, H. Kresse, and K. Walsh Decorin-mediated Signal Transduction in Endothelial Cells. INVOLVEMENT OF Akt/PROTEIN KINASE B IN UP-REGULATION OF p21WAF1/CIP1 BUT NOT p27KIP1 J. Biol. Chem., October 26, 2001; 276(44): 40687 - 40692. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Patel, S. Articles by Thomas, A. P. Search for Related Content PubMed PubMed Citation Articles by Patel, S. Articles by Thomas, A. P.